📍 San Diego, CA·Est. 2022
Altos Labs logo
Private Company

Altos Labs

Longevity biotechnology company pursuing cellular reprogramming to reverse aging. Launched with $3 billion — the largest biotech debut ever — backed by Jeff Bezos and Yuri Milner. Mouse studies show aged organ rejuvenation via Yamanaka factors. Early human safety testing reportedly began August 2025. Appointed Chief Medical Officer in 2025.

Listen to this lesson

Free preview · first 0:30
0:00 / 0:30

Audio & video lessons are paid features

Plus unlocks audio streaming. Pro adds downloadable audio, video, certificates, and more.

Plus adds:
  • Audio streaming
  • Downloadable PDFs
  • All AI Playbooks
  • Personalized content
Pro also adds:
  • Certificates of completion
  • Audio MP3 downloads
  • Video lessonssoon
  • & More…soon

Watch this lesson

Video coming soon

Learn About Altos Labs's AI Products

Create a free account to access in-depth lessons on each tool and model.

Start Learning Free

📋About Altos Labs

Updated June 15, 2026

Altos Labs is a biotechnology company focused on cellular rejuvenation programming, with the ambitious goal of reversing the aging process. Launched in 2022 with $3 billion in funding — the largest biotech debut in history — the company was backed by Jeff Bezos, Yuri Milner, and other prominent investors.

Altos Labs employs leading scientists in the field of epigenetic reprogramming, including Nobel Prize laureate Shinya Yamanaka as a senior scientific advisor. The company's core research uses AI-guided approaches to understand and control Yamanaka factor-mediated cellular reprogramming, which has shown the ability to rejuvenate aged cells and organs in mouse studies. AI and computational biology play a central role in analyzing the molecular pathways of aging and identifying optimal reprogramming strategies.

With research institutes in San Francisco Bay Area, San Diego, Cambridge (UK), and Tokyo, Altos Labs represents one of the largest bets on the convergence of AI and longevity science. Early human safety testing reportedly began in August 2025, marking a critical milestone in translating cellular reprogramming from laboratory research to potential therapeutic applications.

🛠️Products & Tools (1)

AI-guided cellular reprogramming research platform using computational biology and machine learning to identify optimal rejuvenation pathways via Yamanaka factors.

Learn more about Altos Labs

Our curriculum includes an in-depth overview of Altos Labs's strategy, models, and competitive positioning.

View Altos Labs Overview Lesson